BioAtla, Inc.
Pagina dedicata companiei BioAtla, Inc. listata cu simbolul US.BCAB
Descriere companie[edit | ]
BioAtla, Inc. (www.bioatla.com) is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. Its product candidate includes BA3011, BA3021, BA3071. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL. its second product candidate, BA3021, which is a CAB ADC targeting ROR2. Its third product candidate, BA3071, is a CAB anti-CTLA-4 antibody. The Company also uses its CAB technology to develop bispecific antibodies, which bind both a tumor-specific antigen and a T cell receptor using CAB antigen-binding domains. Its bispecific product candidate includes BA3182, BA3142, EGFR and Nectin-4.
Grafic actiuni companie[edit | ]